| Revenue growth | 12% Q-o-Q revenue growth delivered in Q4 FY26. |
|---|---|
| Margins | Base business at 54% gross margin; overall EBITDA margin 16%. |
| Order book | Base business order book remains strong and a primary driver. |
| Demand visibility | Healthy order book in base business; 30% spare capacity available. |
| Management confidence | High in base business; cautious on Ibuprofen turnaround. |
Growth
Revenue grew 12% Q-o-Q; EBITDA grew 65% Q-o-Q to INR 61cr; 16% overall EBITDA margin.
Outlook
Evaluating strategic options for Ibuprofen; aiming to be debt-free by FY29; 4-5 DMF filings planned annually.
Risks
Persistent headwinds in Ibuprofen (negative EBITDA); Middle East crisis impact; reliance on third-party IBB/IBAP sourcing.
Earnings Call filed with BSE, NSE: SOLARA. Summary written with AI assistance from the document.
Solara Active Pharma Sciences Ltd: key numbers
- Share price
- ₹691.70
- Market cap
- ₹3,324 Cr
- Revenue (annual)
- ₹1,369 Cr
- Net profit (annual)
- ₹-7.41 Cr
- P/E (TTM)
- -2052.0×Sector 47.4×
- Promoter holding
- 41.93%-0.07% QoQ
- FII holding
- 11.52%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Solara Active Pharma Sciences Ltd
All →Solara Active Pharma Sciences Other Announcement
Solara Active Pharma Sciences is notifying physical shareholders to update their PAN, KYC, and nomination details per SEBI circulars. This is a routine regulatory compliance intimation.
Solara Active Pharma Sciences Annual General Meeting
Solara Active Pharma Sciences Limited held its Ninth Annual General Meeting on September 18, 2026. Shareholders transacted business, including approving related party transactions.
Solara Active Pharma Sciences Legal & Regulatory
Solara Active Pharma Sciences Limited received a rectification order dropping an earlier income tax demand of Rs. 161.92 Crore. The demand was reduced to nil.
- Value
- ₹161.9 Cr
Solara Active Pharma Sciences Other Announcement
Solara Active Pharma Sciences Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. This is a periodic regulatory compliance disclosure.
Solara Active Pharma Sciences Annual General Meeting
Solara Active Pharma Sciences Limited has issued the notice for its Ninth Annual General Meeting, scheduled to be held on September 18, 2026.
Solara Active Pharma Sciences Capital Structure Change
Solara Active Pharma Sciences approved the conversion of 2,79,582 partly paid-up rights shares into fully paid-up equity. The conversion followed receipt of pending first and final call monies.
- Value
- ₹3.89 Cr